<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20250319205424&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20250319205424&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 20 Mar 2025 00:54:24 +0000</lastbuilddate>
<pubDate>Wed, 19 Mar 2025 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Progression of Atrial Cardiomyopathy Predicts Subsequent Stroke: An Analysis of Left Atrial Low-Voltage Areas in Patients With Atrial Fibrillation Ablation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40104861/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319205424&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Arrhythm Electrophysiol. 2025 Mar 19:e013550. doi: 10.1161/CIRCEP.124.013550. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40104861/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319205424&v=2.18.0.post9+e462414">40104861</a> | DOI:<a href=https://doi.org/10.1161/CIRCEP.124.013550>10.1161/CIRCEP.124.013550</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40104861</guid>
<pubDate>Wed, 19 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Yasuhiro Matsuda</dc:creator>
<dc:creator>Satoshi Kudo</dc:creator>
<dc:creator>Masaharu Masuda</dc:creator>
<dc:creator>Hiroyuki Uematsu</dc:creator>
<dc:creator>Ayako Sugino</dc:creator>
<dc:creator>Hirotaka Ooka</dc:creator>
<dc:creator>Subaru Fujii</dc:creator>
<dc:creator>Shin Okamoto</dc:creator>
<dc:creator>Takayuki Ishihara</dc:creator>
<dc:creator>Kiyonori Nanto</dc:creator>
<dc:creator>Takuya Tsujimura</dc:creator>
<dc:creator>Yosuke Hata</dc:creator>
<dc:creator>Sho Nakao</dc:creator>
<dc:creator>Masaya Kusuda</dc:creator>
<dc:creator>Wataru Ariyasu</dc:creator>
<dc:creator>Toshiaki Mano</dc:creator>
<dc:date>2025-03-19</dc:date>
<dc:source>Circulation. Arrhythmia and electrophysiology</dc:source>
<dc:title>Progression of Atrial Cardiomyopathy Predicts Subsequent Stroke: An Analysis of Left Atrial Low-Voltage Areas in Patients With Atrial Fibrillation Ablation</dc:title>
<dc:identifier>pmid:40104861</dc:identifier>
<dc:identifier>doi:10.1161/CIRCEP.124.013550</dc:identifier>
</item>
<item>
<title>Operator Radiation Exposure Comparing the Left Radial Artery Approach and a Uniform Hyper-Adducted Right Radial Artery Approach: The HARRA Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40104858/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319205424&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The LRA was associated with significantly less cumulative and normalized radiation exposure to the thorax, abdomen, left eye, and right eye of the primary operator compared with HARRA during diagnostic cardiac catheterization. Operators should consider using LRA more frequently than HARRA for diagnostic cardiac catheterization as this approach can reduce occupational radiation exposure.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Cardiovasc Interv. 2025 Mar 19:e014602. doi: 10.1161/CIRCINTERVENTIONS.124.014602. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Radiation exposure is one of the most adverse occupational hazards faced by interventional cardiologists. Various arterial access sites have shown to yield different operator radiation exposure during diagnostic cardiac catheterization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This single-center randomized controlled trial assessed the cumulative radiation exposure and normalized radiation exposure at 4 different anatomic locations (thorax, abdomen, left eye, and right eye) of the primary operator when using the left radial artery (LRA) approach compared with a uniform hyper-adducted right radial artery (HARRA) approach. Patients (n=534) were randomized to LRA (n=269) or HARRA (n=265). During diagnostic catheterization, real-time radiation dosimeters were placed on the thorax, abdomen, left eye, and right eye of each operator.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Cumulative radiation measurements were as follows: thorax (LRA, 9.66±8.57 microsieverts [μSv] versus HARRA, 12.27±7.09 μSv; <i>P</i>&lt;0.001); abdomen (LRA, 27.46±21.20 μSv versus HARRA, 36.56±23.72 μSv; <i>P</i>&lt;0.001); left eye (LRA, 2.65±2.59 μSv versus HARRA, 3.77±2.67 μSv; <i>P</i>&lt;0.001); and right eye (LRA, 1.13±1.69 μSv versus HARRA, 1.44±1.62 μSv; <i>P</i>=0.01). Normalized radiation measurements were: thorax (LRA, 0.38±0.35 versus HARRA, 0.49±0.24; <i>P</i>&lt;0.001); abdomen (LRA, 1.06±0.72 versus HARRA, 1.38±0.69; <i>P</i>&lt;0.001); left eye (LRA, 0.10±0.09 versus HARRA, 0.15±0.10; <i>P</i>&lt;0.001); and right eye: (LRA, 0.04±0.06 versus HARRA, 0.05±0.06; <i>P</i>=0.02). LRA had lower subclavian tortuosity than HARRA (15.6% versus 32.5%, <i>P</i>&lt;0.001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The LRA was associated with significantly less cumulative and normalized radiation exposure to the thorax, abdomen, left eye, and right eye of the primary operator compared with HARRA during diagnostic cardiac catheterization. Operators should consider using LRA more frequently than HARRA for diagnostic cardiac catheterization as this approach can reduce occupational radiation exposure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05833516.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40104858/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319205424&v=2.18.0.post9+e462414">40104858</a> | DOI:<a href=https://doi.org/10.1161/CIRCINTERVENTIONS.124.014602>10.1161/CIRCINTERVENTIONS.124.014602</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40104858</guid>
<pubDate>Wed, 19 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Richard Casazza</dc:creator>
<dc:creator>Bilal Malik</dc:creator>
<dc:creator>Arsalan Hashmi</dc:creator>
<dc:creator>Joshua Fogel</dc:creator>
<dc:creator>Enrico Montagna</dc:creator>
<dc:creator>Robert Frankel</dc:creator>
<dc:creator>Elliot Borgen</dc:creator>
<dc:creator>Sergey Ayzenberg</dc:creator>
<dc:creator>Michael Friedman</dc:creator>
<dc:creator>Norbert Moskovits</dc:creator>
<dc:creator>Shivani Verma</dc:creator>
<dc:creator>Jamie Meng</dc:creator>
<dc:creator>Nailun Chang</dc:creator>
<dc:creator>Yili Huang</dc:creator>
<dc:creator>Carlos Rodriguez</dc:creator>
<dc:creator>Habib Hymie Chera</dc:creator>
<dc:creator>Shiv Raj</dc:creator>
<dc:creator>Saurav Chaterjee</dc:creator>
<dc:creator>Daren Gibson</dc:creator>
<dc:creator>Andres Palacios</dc:creator>
<dc:creator>Chirag Agarwal</dc:creator>
<dc:creator>Maria Victoria Nene</dc:creator>
<dc:creator>Jacob Shani</dc:creator>
<dc:date>2025-03-19</dc:date>
<dc:source>Circulation. Cardiovascular interventions</dc:source>
<dc:title>Operator Radiation Exposure Comparing the Left Radial Artery Approach and a Uniform Hyper-Adducted Right Radial Artery Approach: The HARRA Study</dc:title>
<dc:identifier>pmid:40104858</dc:identifier>
<dc:identifier>doi:10.1161/CIRCINTERVENTIONS.124.014602</dc:identifier>
</item>
<item>
<title>Cardiovascular Toxicity in Patients Treated for Childhood Cancer: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40104841/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319205424&amp;v=2.18.0.post9+e462414
      <description>The field of cardio-oncology has expanded over the past 2 decades to address the ever-increasing issues related to cardiovascular disease in patients with cancer and survivors. There is increasing recognition that nearly all cancer treatments pose some short- or long-term risk for development of cardiovascular disease and that pediatric patients with cancer may be especially vulnerable to cardiovascular disease because of young age at treatment and expected long life span afterward....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Mar 19. doi: 10.1161/CIR.0000000000001308. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The field of cardio-oncology has expanded over the past 2 decades to address the ever-increasing issues related to cardiovascular disease in patients with cancer and survivors. There is increasing recognition that nearly all cancer treatments pose some short- or long-term risk for development of cardiovascular disease and that pediatric patients with cancer may be especially vulnerable to cardiovascular disease because of young age at treatment and expected long life span afterward. Anthracycline chemotherapy and chest-directed radiotherapy are the most well-studied cardiotoxic therapies, and dose reduction, use of cardioprotection for anthracyclines, and modern radiotherapy approaches have contributed to improved cardiovascular outcomes for survivors. Newer treatments such as small-molecule inhibitors, antibody-based cytotoxic therapy, and immunotherapy have expanded options for previously difficult-to-treat cancers but have also revealed new cardiotoxic profiles. Application of effective surveillance strategies in patients with cancer and survivors has been a focus of practitioners and researchers, whereas the prevention and treatment of extant cardiovascular disease is still developing. Incorporation of new strategies in an equitable manner and appropriate transition from pediatric to adult care will greatly influence long-term health-related outcomes in the growing population of childhood cancer survivors at risk for cardiovascular disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40104841/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319205424&v=2.18.0.post9+e462414">40104841</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001308>10.1161/CIR.0000000000001308</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40104841</guid>
<pubDate>Wed, 19 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Thomas D Ryan</dc:creator>
<dc:creator>James E Bates</dc:creator>
<dc:creator>Karen E Kinahan</dc:creator>
<dc:creator>Kasey J Leger</dc:creator>
<dc:creator>Daniel A Mulrooney</dc:creator>
<dc:creator>Hari K Narayan</dc:creator>
<dc:creator>Kirsten Ness</dc:creator>
<dc:creator>Tochukwu M Okwuosa</dc:creator>
<dc:creator>Nino C Rainusso</dc:creator>
<dc:creator>Julia Steinberger</dc:creator>
<dc:creator>Saro H Armenian</dc:creator>
<dc:creator>Pediatric Heart Failure &amp; Transplantation Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology</dc:creator>
<dc:date>2025-03-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiovascular Toxicity in Patients Treated for Childhood Cancer: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:40104841</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001308</dc:identifier>
</item>
<item>
<title>Balloon-expandable stent and self-expandable stent combined to treat coarctation of the aorta with descending aortic aneurysm: a case report</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40103801/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319205424&amp;v=2.18.0.post9+e462414
      <description>BACKGROUND: Coarctation of the aorta is often associated with aortic dilatation, presenting a complex challenge for stent-based interventions. To address this, we have developed a novel combination of stent treatments to manage this dual pathology effectively.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J Case Rep. 2025 Mar 18;9(3):ytaf094. doi: 10.1093/ehjcr/ytaf094. eCollection 2025 Mar.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Coarctation of the aorta is often associated with aortic dilatation, presenting a complex challenge for stent-based interventions. To address this, we have developed a novel combination of stent treatments to manage this dual pathology effectively.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CASE SUMMARY: A 29-year-old hypertensive patient with a coarctation of the aorta and a descending thoracic aortic aneurysm was evaluated for treatment. Contrast-enhanced computed tomography angiography (CTA) revealed significant narrowing at the aortic arch (Zone 2, proximal to the left subclavian artery) with a diameter of 5.04 mm. Additionally, the descending aorta had an aneurysmal dilation measuring 29.65 mm. We applied an innovative approach combining a balloon-expandable stent (BES) with a self-expandable stent (SES). Post-procedure CTA demonstrated favourable aortic remodelling, with the narrowest point of the aorta expanding from 5.04 to 15.95 mm.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DISCUSSION: This novel technique of implanting a BES within an SES effectively addresses both the aortic coarctation and the descending aortic aneurysm. By tripling the diameter of the coarctation, the approach maximizes aortic expansion while protecting the aorta. Moreover, the combination of these stents enhances overall stability, reducing the risk of stent migration or displacement.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40103801/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319205424&v=2.18.0.post9+e462414">40103801</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11914319/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319205424&v=2.18.0.post9+e462414">PMC11914319</a> | DOI:<a href=https://doi.org/10.1093/ehjcr/ytaf094>10.1093/ehjcr/ytaf094</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40103801</guid>
<pubDate>Wed, 19 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Xiaoxue Zhang</dc:creator>
<dc:creator>Shiliang Li</dc:creator>
<dc:creator>Xiantao Ma</dc:creator>
<dc:creator>Wajeehullahi Akilu</dc:creator>
<dc:creator>Cai Cheng</dc:creator>
<dc:date>2025-03-19</dc:date>
<dc:source>European heart journal. Case reports</dc:source>
<dc:title>Balloon-expandable stent and self-expandable stent combined to treat coarctation of the aorta with descending aortic aneurysm: a case report</dc:title>
<dc:identifier>pmid:40103801</dc:identifier>
<dc:identifier>pmc:PMC11914319</dc:identifier>
<dc:identifier>doi:10.1093/ehjcr/ytaf094</dc:identifier>
</item>
<item>
<title>Left atrial veno-arterial extracorporeal membrane oxygenation as a bridge to surgical or percutaneous closure of post-myocardial infarction ventriculoseptal defects: a case series</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40103800/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319205424&amp;v=2.18.0.post9+e462414
      <description>BACKGROUND: Post-myocardial infarct (MI) ventricular septal defect (VSD) is a rare and severe complication of an acute MI with high mortality rate. The use of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) as a bridge to surgical or percutaneous repair in cardiogenic shock secondary to post-MI-VSD has been published, but is limited to small case series primarily utilizing surgical ECMO, with the main drawback of potentially increasing afterload and left ventricle pressure, further...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J Case Rep. 2025 Feb 25;9(3):ytaf095. doi: 10.1093/ehjcr/ytaf095. eCollection 2025 Mar.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Post-myocardial infarct (MI) ventricular septal defect (VSD) is a rare and severe complication of an acute MI with high mortality rate. The use of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) as a bridge to surgical or percutaneous repair in cardiogenic shock secondary to post-MI-VSD has been published, but is limited to small case series primarily utilizing surgical ECMO, with the main drawback of potentially increasing afterload and left ventricle pressure, further worsening VSD shunting. Left-atrial VA-ECMO (LAVA-ECMO) can potentially absolve this concern given that it utilizes bi-atrial drainage through a trans-septal fenestrated cannula.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CASE SUMMARY: Five patients were included in this series, all with VSD secondary to MI, and all managed with LAVA-ECMO as a bridge to repair. Average age was 62 ± 4.2 years, body mass index of 29.4 ± 4.5 kg/m<sup>2</sup>, and left ventricular ejection fraction of 46.6 ± 13.8%. Haemodynamics monitoring pre- and post-LAVA-ECMO demonstrated improvement in right atrial, right ventricular, pulmonary, left atrial, and left ventricular pressures (<i>Figure 1</i>). Average time to repair was 7.4 ± 3.9 days. All five patients survived to repair, with four undergoing surgical and one undergoing percutaneous closure. Four out of five patients were decannulated successfully.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DISCUSSION: This case series reports the successful use of LAVA-ECMO as a bridge to MI-VSD repair in patients with cardiogenic shock. Left-atrial VA-ECMO serves as a convenient approach to managing patients with MI-VSD related cardiogenic shock as it is implanted percutaneously, and can be done at the time of shock diagnosis, during right heart catheterization by trained interventionists.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40103800/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319205424&v=2.18.0.post9+e462414">40103800</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11914317/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319205424&v=2.18.0.post9+e462414">PMC11914317</a> | DOI:<a href=https://doi.org/10.1093/ehjcr/ytaf095>10.1093/ehjcr/ytaf095</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40103800</guid>
<pubDate>Wed, 19 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Raef Fadel</dc:creator>
<dc:creator>Jessica Elderkin</dc:creator>
<dc:creator>Hussayn Alrayes</dc:creator>
<dc:creator>Gennaro Giustino</dc:creator>
<dc:creator>Tiberio Frisoli</dc:creator>
<dc:creator>Mir Babar Basir</dc:creator>
<dc:creator>Dimitrios Apostolou</dc:creator>
<dc:creator>Pedro Villablanca</dc:creator>
<dc:date>2025-03-19</dc:date>
<dc:source>European heart journal. Case reports</dc:source>
<dc:title>Left atrial veno-arterial extracorporeal membrane oxygenation as a bridge to surgical or percutaneous closure of post-myocardial infarction ventriculoseptal defects: a case series</dc:title>
<dc:identifier>pmid:40103800</dc:identifier>
<dc:identifier>pmc:PMC11914317</dc:identifier>
<dc:identifier>doi:10.1093/ehjcr/ytaf095</dc:identifier>
</item>
<item>
<title>Possible solution for coronary cannulation through complete anti-anatomical deployment of self-expandable transcatheter heart valve using handmade spiral curve of catheter created by heat-gun</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40103799/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319205424&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J Case Rep. 2025 Mar 18;9(3):ytaf011. doi: 10.1093/ehjcr/ytaf011. eCollection 2025 Mar.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40103799/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319205424&v=2.18.0.post9+e462414">40103799</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11913563/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319205424&v=2.18.0.post9+e462414">PMC11913563</a> | DOI:<a href=https://doi.org/10.1093/ehjcr/ytaf011>10.1093/ehjcr/ytaf011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40103799</guid>
<pubDate>Wed, 19 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Masanori Yamamoto</dc:creator>
<dc:creator>Hirooki Higami</dc:creator>
<dc:creator>Yuki Kondo</dc:creator>
<dc:creator>Fubuki Kitahara</dc:creator>
<dc:date>2025-03-19</dc:date>
<dc:source>European heart journal. Case reports</dc:source>
<dc:title>Possible solution for coronary cannulation through complete anti-anatomical deployment of self-expandable transcatheter heart valve using handmade spiral curve of catheter created by heat-gun</dc:title>
<dc:identifier>pmid:40103799</dc:identifier>
<dc:identifier>pmc:PMC11913563</dc:identifier>
<dc:identifier>doi:10.1093/ehjcr/ytaf011</dc:identifier>
</item>
<item>
<title>Haemodynamic spectrum in heritable pulmonary arterial hypertension: a continuum from pre-capillary to combined pulmonary hypertension-case series</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40103798/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319205424&amp;v=2.18.0.post9+e462414
      <description>BACKGROUND: Heritable pulmonary arterial hypertension (PAH) is a rare form of pre-capillary pulmonary hypertension that typically affects young patients. With increased survival and subsequent ageing of these patients, newly acquired cardiovascular conditions may influence the pulmonary haemodynamic profile and impact management.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J Case Rep. 2025 Feb 26;9(3):ytaf109. doi: 10.1093/ehjcr/ytaf109. eCollection 2025 Mar.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Heritable pulmonary arterial hypertension (PAH) is a rare form of pre-capillary pulmonary hypertension that typically affects young patients. With increased survival and subsequent ageing of these patients, newly acquired cardiovascular conditions may influence the pulmonary haemodynamic profile and impact management.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CASE SUMMARY: We report a case series of four patients with mutations in genes associated with PAH to illustrate the spectrum of pulmonary haemodynamics under the influence of superimposed acquired conditions. The first two cases involve patients with a long-standing diagnosis of heritable PAH and severe pre-capillary pulmonary hypertension, who developed overt left-sided diastolic dysfunction later in follow-up due to the acquisition of multiple cardiovascular comorbidities. The second two cases describe patients with a genetic pre-disposition to develop PAH and conditions that are risk factors for left heart disease, with mild elevation of resting pulmonary pressures, in whom exercise right heart catheterization unmasked occult left-sided diastolic dysfunction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DISCUSSION: Pulmonary haemodynamics are complex and dynamic over time, even in patients with or at risk of heritable PAH, when additional acquired cardiovascular conditions emerge. Correct phenotyping at diagnosis and during follow-up of patients at risk of heritable PAH, along with a clear understanding of the underlying pulmonary haemodynamic profile, is crucial for appropriate management.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40103798/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319205424&v=2.18.0.post9+e462414">40103798</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11913607/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319205424&v=2.18.0.post9+e462414">PMC11913607</a> | DOI:<a href=https://doi.org/10.1093/ehjcr/ytaf109>10.1093/ehjcr/ytaf109</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40103798</guid>
<pubDate>Wed, 19 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Irene Martín de Miguel</dc:creator>
<dc:creator>Alejandro Cruz Utrilla</dc:creator>
<dc:creator>Teresa Segura de La Cal</dc:creator>
<dc:creator>Fernando Sarnago Cebada</dc:creator>
<dc:creator>Maite Velázquez Martín</dc:creator>
<dc:creator>Carmen Jiménez López-Guarch</dc:creator>
<dc:creator>Fernando Arribas Ynsaurriaga</dc:creator>
<dc:creator>Pilar Escribano Subías</dc:creator>
<dc:date>2025-03-19</dc:date>
<dc:source>European heart journal. Case reports</dc:source>
<dc:title>Haemodynamic spectrum in heritable pulmonary arterial hypertension: a continuum from pre-capillary to combined pulmonary hypertension-case series</dc:title>
<dc:identifier>pmid:40103798</dc:identifier>
<dc:identifier>pmc:PMC11913607</dc:identifier>
<dc:identifier>doi:10.1093/ehjcr/ytaf109</dc:identifier>
</item>
<item>
<title>Ligand-induced ubiquitination unleashes LAG3 immune checkpoint function by hindering membrane sequestration of signaling motifs</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40101708/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319205424&amp;v=2.18.0.post9+e462414
      <description>Lymphocyte activation gene 3 (LAG3) has emerged as a promising cancer immunotherapy target, but the mechanism underlying LAG3 activation upon ligand engagement remains elusive. Here, LAG3 was found to undergo robust non-K48-linked polyubiquitination upon ligand engagement, which promotes LAG3's inhibitory function instead of causing degradation. This ubiquitination could be triggered by the engagement of major histocompatibility complex class II (MHC class II) and membrane-bound (but not...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Mar 6:S0092-8674(25)00199-0. doi: 10.1016/j.cell.2025.02.014. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Lymphocyte activation gene 3 (LAG3) has emerged as a promising cancer immunotherapy target, but the mechanism underlying LAG3 activation upon ligand engagement remains elusive. Here, LAG3 was found to undergo robust non-K48-linked polyubiquitination upon ligand engagement, which promotes LAG3's inhibitory function instead of causing degradation. This ubiquitination could be triggered by the engagement of major histocompatibility complex class II (MHC class II) and membrane-bound (but not soluble) fibrinogen-like protein 1 (FGL1). LAG3 ubiquitination, mediated redundantly by the E3 ligases c-Cbl and Cbl-b, disrupted the membrane binding of the juxtamembrane basic residue-rich sequence, thereby stabilizing the LAG3 cytoplasmic tail in a membrane-dissociated conformation enabling signaling. Furthermore, LAG3 ubiquitination is crucial for the LAG3-mediated suppression of antitumor immunity in vivo. Consistently, LAG3 therapeutic antibodies repress LAG3 ubiquitination, correlating with their checkpoint blockade effects. Moreover, patient cohort analyses suggest that LAG3/CBL coexpression could serve as a biomarker for response to LAG3 blockade. Collectively, our study reveals an immune-checkpoint-triggering mechanism with translational potential in cancer immunotherapy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40101708/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319205424&v=2.18.0.post9+e462414">40101708</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.02.014>10.1016/j.cell.2025.02.014</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40101708</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Yong Jiang</dc:creator>
<dc:creator>Anran Dai</dc:creator>
<dc:creator>Yuwei Huang</dc:creator>
<dc:creator>Hua Li</dc:creator>
<dc:creator>Jian Cui</dc:creator>
<dc:creator>Haochen Yang</dc:creator>
<dc:creator>Lu Si</dc:creator>
<dc:creator>Tao Jiao</dc:creator>
<dc:creator>Zhengxu Ren</dc:creator>
<dc:creator>Ziwei Zhang</dc:creator>
<dc:creator>Si Mou</dc:creator>
<dc:creator>Hengrui Zhu</dc:creator>
<dc:creator>Wenhui Guo</dc:creator>
<dc:creator>Qiang Huang</dc:creator>
<dc:creator>Yilin Li</dc:creator>
<dc:creator>Manman Xue</dc:creator>
<dc:creator>Jingwei Jiang</dc:creator>
<dc:creator>Fei Wang</dc:creator>
<dc:creator>Li Li</dc:creator>
<dc:creator>Qinying Zhong</dc:creator>
<dc:creator>Kun Wang</dc:creator>
<dc:creator>Baichuan Liu</dc:creator>
<dc:creator>Jinjiao Wang</dc:creator>
<dc:creator>Gaofeng Fan</dc:creator>
<dc:creator>Jun Guo</dc:creator>
<dc:creator>Liang Chen</dc:creator>
<dc:creator>Creg J Workman</dc:creator>
<dc:creator>Zhirong Shen</dc:creator>
<dc:creator>Yan Kong</dc:creator>
<dc:creator>Dario A A Vignali</dc:creator>
<dc:creator>Chenqi Xu</dc:creator>
<dc:creator>Haopeng Wang</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Ligand-induced ubiquitination unleashes LAG3 immune checkpoint function by hindering membrane sequestration of signaling motifs</dc:title>
<dc:identifier>pmid:40101708</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.02.014</dc:identifier>
</item>
<item>
<title>Left atrial intramural hematoma after ventricular radiofrequency catheter ablation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40101156/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319205424&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J Cardiovasc Imaging. 2025 Mar 18:jeaf091. doi: 10.1093/ehjci/jeaf091. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40101156/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319205424&v=2.18.0.post9+e462414">40101156</a> | DOI:<a href=https://doi.org/10.1093/ehjci/jeaf091>10.1093/ehjci/jeaf091</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40101156</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Alan Diniz Hummel</dc:creator>
<dc:creator>André Vaz</dc:creator>
<dc:creator>André Paciello Romualdo</dc:creator>
<dc:creator>Andrei Skromov de Albuquerque</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>European heart journal. Cardiovascular Imaging</dc:source>
<dc:title>Left atrial intramural hematoma after ventricular radiofrequency catheter ablation</dc:title>
<dc:identifier>pmid:40101156</dc:identifier>
<dc:identifier>doi:10.1093/ehjci/jeaf091</dc:identifier>
</item>
<item>
<title>Hybrid Versus Percutaneous Left Atrial Decompression in Infants With Hypoplastic Left Heart Variants and an Intact or Highly Restrictive Atrial Septum: A Multicenter PICES Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40100953/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319205424&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with HLH-IAS, hybrid LAD allows for faster atrial septal defect creation, has a higher technical success rate, and potentially fewer procedural serious adverse events compared with percutaneous LAD, alongside facilitating simultaneous pulmonary artery band. Our findings underscore the poor prognosis for patients with HLH-IAS despite intervention, highlighting the need for better treatment strategies.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Cardiovasc Interv. 2025 Mar;18(3):e014243. doi: 10.1161/CIRCINTERVENTIONS.124.014243. Epub 2025 Mar 18.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Neonates with hypoplastic left heart syndrome variants with an intact or highly restrictive atrial septum (HLH-IAS) require immediate postnatal intervention to survive. Emergent left atrial decompression (LAD) via a percutaneous or hybrid approach is standard, but the comparative effectiveness and outcomes of these approaches remain underexplored.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A multicenter retrospective analysis of all neonates with HLH-IAS who underwent LAD in the first 36 hours of life from January 2009 to March 2020 at 14 North American congenital cardiac programs was conducted. Patient and procedural characteristics and patient outcomes were compared between hybrid and percutaneous LAD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 128 patients with HLH-IAS, 105 (80%) underwent percutaneous LAD and 23 (17%) hybrid LAD. No significant differences were observed in preprocedural characteristics such as birth weight (3.1±0.6 versus 3.2±0.6 kg; <i>P</i>=0.453), presence of a baseline interatrial communication (66% versus 61%; <i>P</i>=0.659), interatrial communication gradient (14.4±6.9 versus 12.7±4.6 mm Hg; <i>P</i>=0.456), or lowest pH (7.13±0.14 versus 7.09±0.15; <i>P</i>=0.193). Hybrid LAD resulted in a shorter time from birth to procedure (120 versus 52 minutes; <i>P</i>=0.005) and to atrial septal defect creation (55 versus 29 minutes; <i>P</i>=0.002). All hybrid LAD were technically successful, although 11 (10%) percutaneous LAD were unsuccessful with 7 requiring conversion to surgical septectomy. There was a trend toward fewer serious adverse events with hybrid LAD (36% versus 17%; <i>P</i>=0.141). Most patients (67%) who underwent hybrid LAD had simultaneous pulmonary artery band placement and 21% of patients with percutaneous LAD required reoperation for pulmonary artery band. Long-term survival rates were comparably low between groups, with a 30% transplant-free survival at a median 8-month follow-up.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with HLH-IAS, hybrid LAD allows for faster atrial septal defect creation, has a higher technical success rate, and potentially fewer procedural serious adverse events compared with percutaneous LAD, alongside facilitating simultaneous pulmonary artery band. Our findings underscore the poor prognosis for patients with HLH-IAS despite intervention, highlighting the need for better treatment strategies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40100953/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319205424&v=2.18.0.post9+e462414">40100953</a> | DOI:<a href=https://doi.org/10.1161/CIRCINTERVENTIONS.124.014243>10.1161/CIRCINTERVENTIONS.124.014243</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40100953</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Konstantin Averin</dc:creator>
<dc:creator>Michael D Seckeler</dc:creator>
<dc:creator>Holly Bauser-Heaton</dc:creator>
<dc:creator>Matthew C Schwartz</dc:creator>
<dc:creator>Paul Tannous</dc:creator>
<dc:creator>Cameron Seaman</dc:creator>
<dc:creator>Wendy Whiteside</dc:creator>
<dc:creator>George T Nicholson</dc:creator>
<dc:creator>Priti M Patel</dc:creator>
<dc:creator>Brent M Gordon</dc:creator>
<dc:creator>Ryan A Romans</dc:creator>
<dc:creator>Rajiv Devanagondi</dc:creator>
<dc:creator>Carrie E Herbert</dc:creator>
<dc:creator>Sarosh P Batlivala</dc:creator>
<dc:creator>Brian Boe</dc:creator>
<dc:creator>Gurumurthy Hiremath</dc:creator>
<dc:creator>Jeffrey D Zampi</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Circulation. Cardiovascular interventions</dc:source>
<dc:title>Hybrid Versus Percutaneous Left Atrial Decompression in Infants With Hypoplastic Left Heart Variants and an Intact or Highly Restrictive Atrial Septum: A Multicenter PICES Study</dc:title>
<dc:identifier>pmid:40100953</dc:identifier>
<dc:identifier>doi:10.1161/CIRCINTERVENTIONS.124.014243</dc:identifier>
</item>
<item>
<title>PCI for Surgically Ineligible Patients: Another Piece of the Jigsaw</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40100952/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319205424&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Cardiovasc Interv. 2025 Mar;18(3):e015200. doi: 10.1161/CIRCINTERVENTIONS.125.015200. Epub 2025 Mar 18.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40100952/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319205424&v=2.18.0.post9+e462414">40100952</a> | DOI:<a href=https://doi.org/10.1161/CIRCINTERVENTIONS.125.015200>10.1161/CIRCINTERVENTIONS.125.015200</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40100952</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Tim Kinnaird</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Circulation. Cardiovascular interventions</dc:source>
<dc:title>PCI for Surgically Ineligible Patients: Another Piece of the Jigsaw</dc:title>
<dc:identifier>pmid:40100952</dc:identifier>
<dc:identifier>doi:10.1161/CIRCINTERVENTIONS.125.015200</dc:identifier>
</item>
<item>
<title>Temporal Changes in Procedural Success and Clinical Outcomes of MTEER by Mechanism of MR: Analysis of the STS/TVT Registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40100951/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319205424&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The application of mitral transcatheter edge-to-edge repair for nondegenerative etiologies increased considerably. While the odds of technical success were higher for all etiologies except acute ischemic MR, a similar 1-year mortality risk was observed in nondegenerative etiologies compared with DMR in real-world settings. These data support the use of mitral transcatheter edge-to-edge repair in degenerative and nondegenerative etiologies.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Cardiovasc Interv. 2025 Mar;18(3):e014819. doi: 10.1161/CIRCINTERVENTIONS.124.014819. Epub 2025 Mar 18.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: With the expansion of indications for mitral transcatheter edge-to-edge repair into nondegenerative etiologies, it is unknown whether changes in technical success and clinical outcomes have occurred.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy (STS/TVT) registry was analyzed from 2013 to 2023. Patients in shock were excluded. Patients were grouped by the mechanism of mitral regurgitation (MR) and divided into time periods.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall, 68 028 patients were included. The application of mitral transcatheter edge-to-edge repair has evolved over the past decade to include more nondegenerative etiologies-increasing from 19% to 43%. The biggest growth was observed in functional MR (atrial and ventricular). Excluding acute ischemic MR, the odds of technical success were significantly higher for all mechanisms compared with degenerative MR (DMR). Over time more procedures were performed using only 1 implanted device (64.7% during 2022-2023 versus 54.6% during 2013-2017), without negatively impacting technical success. In multivariable analyses, the risk of 1-year heart failure readmission for ventricular functional MR was not higher than for DMR (<i>P</i>=0.10642), while patients with chronic ischemic MR and atrial MR had a 19% higher risk of 1-year heart failure readmission compared with DMR (<i>P</i>=0.00493) even if they had a successful procedure. However, the risk of 1-year mortality was not higher in nondegenerative etiologies compared with DMR. There was no statistically significant interaction between MR mechanism and time in outcomes analyses, indicating that the effect of MR mechanism on the technical and 1-year clinical outcomes did not vary significantly over time.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The application of mitral transcatheter edge-to-edge repair for nondegenerative etiologies increased considerably. While the odds of technical success were higher for all etiologies except acute ischemic MR, a similar 1-year mortality risk was observed in nondegenerative etiologies compared with DMR in real-world settings. These data support the use of mitral transcatheter edge-to-edge repair in degenerative and nondegenerative etiologies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40100951/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319205424&v=2.18.0.post9+e462414">40100951</a> | DOI:<a href=https://doi.org/10.1161/CIRCINTERVENTIONS.124.014819>10.1161/CIRCINTERVENTIONS.124.014819</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40100951</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Zach Rozenbaum</dc:creator>
<dc:creator>Sreekanth Vemulapalli</dc:creator>
<dc:creator>Miloni Shah</dc:creator>
<dc:creator>Andrzej Stanislaw Kosinski</dc:creator>
<dc:creator>Eric Gnall</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Circulation. Cardiovascular interventions</dc:source>
<dc:title>Temporal Changes in Procedural Success and Clinical Outcomes of MTEER by Mechanism of MR: Analysis of the STS/TVT Registry</dc:title>
<dc:identifier>pmid:40100951</dc:identifier>
<dc:identifier>doi:10.1161/CIRCINTERVENTIONS.124.014819</dc:identifier>
</item>
<item>
<title>Impact of Bypass Conduit and Early Technical Failure on Revascularization for Chronic Limb-Threatening Ischemia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40100950/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319205424&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Analysis of as-treated outcomes from the BEST-CLI trial demonstrates the safety and clinical superiority of bypass with SSGSV among patients with CLTI who were deemed suitable for either open surgical bypass or ENDO revascularization. Assessment of great saphenous vein quality should be incorporated into the evaluation of patients with CLTI who are surgical candidates.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Cardiovasc Interv. 2025 Mar;18(3):e014716. doi: 10.1161/CIRCINTERVENTIONS.124.014716. Epub 2025 Mar 18.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The optimal strategy for lower extremity revascularization (surgical bypass versus endovascular intervention) in patients with chronic limb-threatening ischemia (CLTI) is unclear. We examined the effectiveness of open surgical bypass using single-segment great saphenous vein conduit (SSGSV), alternative conduits (AC), or endovascular interventions (ENDO) among patients with CLTI deemed acceptable for either open surgical bypass or ENDO treatment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This was a planned as-treated analysis of the multicenter BEST-CLI (Best Endovascular Versus Best Surgical Therapy in Patients With Critical Limb Ischemia) randomized controlled trial comparing open surgical bypass and ENDO for CLTI due to infrainguinal peripheral artery disease. Outcomes were tabulated based on the initial revascularization received: SSGSV bypass, AC bypass, and ENDO. Analyses were performed for all treated patients and then excluding those who experienced early technical failure. Multivariable Cox regression models were used. End points included the primary trial outcome (major adverse limb event [MALE] or all-cause death), major amputation, MALE at any time or perioperative (30-day) death, reintervention-amputation-death, and all-cause mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 1780 patients with CLTI, treatments received included SSGSV bypass (n=621), AC bypass (n=236), and ENDO (n=923) procedures. There were no significant differences in 30-day mortality, major adverse cardiovascular events, or serious adverse events; subjects treated with ENDO experienced greater MALE within 30 days (13.1% versus 2.7%, 3% for SSGSV, AC; <i>P</i>&lt;0.001). On risk-adjusted analysis, SSGSV bypass was associated with reduced MALE or all-cause death (hazard ratio, 0.65 [95% CI, 0.56-0.76]; <i>P</i>&lt;0.001), major amputation (hazard ratio, 0.70 [95% CI, 0.52-0.94]; <i>P</i>=0.017), MALE or perioperative death (hazard ratio, 0.51 [0.41-0.62]; <i>P</i>&lt;0.001), and reintervention-amputation-death (hazard ratio, 0.69 [95% CI, 0.61-0.79]; <i>P</i>&lt;0.001). AC bypass was associated with reduced MALE or perioperative death and reintervention-amputation-death compared with ENDO. Significant benefits of SSGSV over ENDO remained when excluding patients who experienced early technical failure. There were no significant differences in long-term mortality by initial treatment received. When analyzed by the level of disease treated, the improved outcomes of SSGSV were greatest among patients who underwent femoropopliteal revascularization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Analysis of as-treated outcomes from the BEST-CLI trial demonstrates the safety and clinical superiority of bypass with SSGSV among patients with CLTI who were deemed suitable for either open surgical bypass or ENDO revascularization. Assessment of great saphenous vein quality should be incorporated into the evaluation of patients with CLTI who are surgical candidates.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifiers: NCT02060630 and NCT02060630.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40100950/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319205424&v=2.18.0.post9+e462414">40100950</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11921934/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319205424&v=2.18.0.post9+e462414">PMC11921934</a> | DOI:<a href=https://doi.org/10.1161/CIRCINTERVENTIONS.124.014716>10.1161/CIRCINTERVENTIONS.124.014716</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40100950</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Michael S Conte</dc:creator>
<dc:creator>Alik Farber</dc:creator>
<dc:creator>Andrew Barleben</dc:creator>
<dc:creator>Emiliano Chisci</dc:creator>
<dc:creator>Gheorghe Doros</dc:creator>
<dc:creator>Vikram S Kashyap</dc:creator>
<dc:creator>Ahmed Kayssi</dc:creator>
<dc:creator>Philippe Kolh</dc:creator>
<dc:creator>Carla C Moreira</dc:creator>
<dc:creator>Timothy Nypaver</dc:creator>
<dc:creator>Kenneth Rosenfield</dc:creator>
<dc:creator>Vincent L Rowe</dc:creator>
<dc:creator>Andres Schanzer</dc:creator>
<dc:creator>Niten Singh</dc:creator>
<dc:creator>Jeffrey J Siracuse</dc:creator>
<dc:creator>Michael B Strong</dc:creator>
<dc:creator>Matthew T Menard</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Circulation. Cardiovascular interventions</dc:source>
<dc:title>Impact of Bypass Conduit and Early Technical Failure on Revascularization for Chronic Limb-Threatening Ischemia</dc:title>
<dc:identifier>pmid:40100950</dc:identifier>
<dc:identifier>pmc:PMC11921934</dc:identifier>
<dc:identifier>doi:10.1161/CIRCINTERVENTIONS.124.014716</dc:identifier>
</item>
<item>
<title>Characteristics and Outcomes of PCI Among Patients Ineligible for Surgical Revascularization in the Veterans Affairs Healthcare System</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40100949/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319205424&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Ineligibility for surgical revascularization was associated with increased risk of long-term mortality after PCI. The risk of adverse outcomes after PCI, however, was similar among surgically eligible and ineligible patients after adjusting for measured comorbidities, coronary anatomic features, and procedural complexity.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Cardiovasc Interv. 2025 Mar;18(3):e014899. doi: 10.1161/CIRCINTERVENTIONS.124.014899. Epub 2025 Mar 18.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Ineligibility for surgical revascularization is increasingly prevalent and associated with increased mortality after percutaneous coronary intervention (PCI). High-quality, contemporary, multicenter data regarding clinical outcomes after PCI is scarce and poses a barrier to clinical decision-making for surgically ineligible patients. The aim of this study was to describe and compare the clinical characteristics, institutional variation, and longitudinal outcomes of PCI among surgically eligible and ineligible patients in the Veterans Affairs Healthcare System.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients with left main and/or multivessel coronary artery disease undergoing index PCI between October 1, 2017 and September 30, 2022 were identified and the prevalence of surgical ineligibility determined by review of the electronic medical record. The association between surgical ineligibility and mortality and major adverse cardiovascular events (MACE; death, myocardial infarction, repeat revascularization, and stroke) was assessed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 6192 patients with left main and/or multivessel coronary artery disease (842 surgically ineligible and 5350 surgically eligible) underwent PCI during the study period. After adjustment, surgical ineligibility was associated with a significantly decreased time to mortality (time ratio, 0.801 [95% CI, 0.662-0.970]) over a median 1045-day (interquartile range, 583-1600) follow-up period, though not associated with composite MACE (time ratio, 0.859 [95% CI, 0.685-1.078]). After adjustment for target lesion characteristics and procedural complexity, the association between surgical ineligibility and mortality was attenuated (time ratio, 0.842 [95% CI, 0.688-1.030]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Ineligibility for surgical revascularization was associated with increased risk of long-term mortality after PCI. The risk of adverse outcomes after PCI, however, was similar among surgically eligible and ineligible patients after adjusting for measured comorbidities, coronary anatomic features, and procedural complexity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40100949/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319205424&v=2.18.0.post9+e462414">40100949</a> | DOI:<a href=https://doi.org/10.1161/CIRCINTERVENTIONS.124.014899>10.1161/CIRCINTERVENTIONS.124.014899</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40100949</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Christopher P Kovach</dc:creator>
<dc:creator>Jerry Lipinski</dc:creator>
<dc:creator>Elise C Mesenbring</dc:creator>
<dc:creator>Peter Boulos</dc:creator>
<dc:creator>Abby Pribish</dc:creator>
<dc:creator>Michael Sola</dc:creator>
<dc:creator>Thomas J Glorioso</dc:creator>
<dc:creator>William F Fearon</dc:creator>
<dc:creator>Robert W Yeh</dc:creator>
<dc:creator>Stephen W Waldo</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Circulation. Cardiovascular interventions</dc:source>
<dc:title>Characteristics and Outcomes of PCI Among Patients Ineligible for Surgical Revascularization in the Veterans Affairs Healthcare System</dc:title>
<dc:identifier>pmid:40100949</dc:identifier>
<dc:identifier>doi:10.1161/CIRCINTERVENTIONS.124.014899</dc:identifier>
</item>
<item>
<title>Intravascular Imaging-Guided Versus Angiography-Guided Complex PCI in Patients With High Bleeding Risk: A Secondary Analysis of the RENOVATE-COMPLEX PCI Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40100948/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319205424&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Patients with HBR were associated with an increased risk of adverse cardiovascular events after complex PCI compared with those without HBR. Intravascular imaging-guided PCI showed a lower risk of the target vessel failure without significant interaction between treatment strategy and the presence of HBR in patients undergoing complex PCI.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Cardiovasc Interv. 2025 Mar;18(3):e014952. doi: 10.1161/CIRCINTERVENTIONS.124.014952. Epub 2025 Mar 18.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Although patients with high bleeding risk (HBR) often have complex coronary artery lesions, it is not known whether intravascular imaging-guided percutaneous coronary intervention (PCI) improves their prognosis. We sought to investigate the benefit of intravascular imaging-guided PCI for complex coronary artery lesions in patients with HBR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This was a secondary analysis of the RENOVATE-COMPLEX-PCI trial (Randomized Controlled Trial of Intravascular Imaging Guidance Versus Angiography-Guidance on Clinical Outcomes After Complex Percutaneous Coronary Intervention) in which patients with complex coronary artery lesions undergoing PCI were enrolled at 20 sites in Korea from May 2018 through May 2021. Patients were randomized to receive intravascular imaging-guided PCI or angiography-guided PCI and classified according to the presence of HBR. The primary end point was target vessel failure, which was a composite of cardiac death, target vessel-related myocardial infarction, or clinically driven target vessel revascularization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 1639 trial population, 478 patients met HBR criteria. There was no significant difference in the risk of the primary end point between HBR and non-HBR patients (11.8% versus 8.2%; adjusted hazard ratio [HR], 1.05 [95% CI, 0.72-1.54]; <i>P</i>=0.790). However, patients with HBR were at higher risk for cardiac death or spontaneous target vessel-related myocardial infarction (adjusted HR, 2.04 [95% CI, 1.09-3.80]; <i>P</i>=0.025), all-cause death (adjusted HR, 3.30 [95% CI, 1.93-5.62]; <i>P</i>&lt;0.001), and cardiac death (adjusted HR, 2.36 [95% CI, 1.10-5.09]; <i>P</i>=0.028). Intravascular imaging-guided PCI showed a lower risk of the primary end point compared with angiography-guided PCI in both HBR patients (9.7% versus 15.8%; adjusted HR, 0.57 [95% CI, 0.31-1.02]; <i>P</i>=0.060) and non-HBR patients (6.9% versus 10.8%; adjusted HR, 0.65 [95% CI, 0.43-0.99]; <i>P</i>=0.045), without significant interaction (<i>P</i> for interaction=0.796).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Patients with HBR were associated with an increased risk of adverse cardiovascular events after complex PCI compared with those without HBR. Intravascular imaging-guided PCI showed a lower risk of the target vessel failure without significant interaction between treatment strategy and the presence of HBR in patients undergoing complex PCI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03381872.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40100948/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319205424&v=2.18.0.post9+e462414">40100948</a> | DOI:<a href=https://doi.org/10.1161/CIRCINTERVENTIONS.124.014952>10.1161/CIRCINTERVENTIONS.124.014952</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40100948</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Jinhwan Jo</dc:creator>
<dc:creator>Sang Yoon Lee</dc:creator>
<dc:creator>Woochan Kwon</dc:creator>
<dc:creator>Seung-Jae Lee</dc:creator>
<dc:creator>Jong-Young Lee</dc:creator>
<dc:creator>Seung Hun Lee</dc:creator>
<dc:creator>Doosup Shin</dc:creator>
<dc:creator>Sang Min Kim</dc:creator>
<dc:creator>Kyeong Ho Yun</dc:creator>
<dc:creator>Jae Young Cho</dc:creator>
<dc:creator>Chan Joon Kim</dc:creator>
<dc:creator>Hyo-Suk Ahn</dc:creator>
<dc:creator>Chang-Wook Nam</dc:creator>
<dc:creator>Hyuck-Jun Yoon</dc:creator>
<dc:creator>Yong Hwan Park</dc:creator>
<dc:creator>Wang Soo Lee</dc:creator>
<dc:creator>Ki Hong Choi</dc:creator>
<dc:creator>Taek Kyu Park</dc:creator>
<dc:creator>Jeong Hoon Yang</dc:creator>
<dc:creator>Seung-Hyuk Choi</dc:creator>
<dc:creator>Hyeon-Cheol Gwon</dc:creator>
<dc:creator>Young Bin Song</dc:creator>
<dc:creator>Joo-Yong Hahn</dc:creator>
<dc:creator>Sang Yeub Lee</dc:creator>
<dc:creator>Joo Myung Lee</dc:creator>
<dc:creator>RENOVATE-COMPLEX-PCI Investigators</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Circulation. Cardiovascular interventions</dc:source>
<dc:title>Intravascular Imaging-Guided Versus Angiography-Guided Complex PCI in Patients With High Bleeding Risk: A Secondary Analysis of the RENOVATE-COMPLEX PCI Trial</dc:title>
<dc:identifier>pmid:40100948</dc:identifier>
<dc:identifier>doi:10.1161/CIRCINTERVENTIONS.124.014952</dc:identifier>
</item>
<item>
<title>Prognosis and Risk Stratification in Dilated Cardiomyopathy With LVEF≤35%: Cardiac MRI Insights for Better Outcomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40100943/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319205424&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Patients with dilated cardiomyopathy with late gadolinium enhancement≥7.5% were at heightened risk of SCD events, which can be used for risk assessment. Risk stratifications for SCD, combining clinical and cardiac magnetic resonance imaging may potentially guide decision-making for implantable cardioverter defibrillator therapy.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Cardiovasc Imaging. 2025 Mar;18(3):e017246. doi: 10.1161/CIRCIMAGING.124.017246. Epub 2025 Mar 18.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Current guidelines recommend implantable cardioverter defibrillators for the primary prevention of sudden cardiac death (SCD) in patients with dilated cardiomyopathy with left ventricular ejection fraction (LVEF)≤35%. However, its effectiveness is hindered by the inability to reliably discriminate between the risk of SCD and competing death of heart failure deterioration, thereby limiting its clinical utility. We aimed to refine the SCD risk stratification model based on cardiac magnetic resonance imaging for patients with dilated cardiomyopathy with LVEF≤35%.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 1272 patients with dilated cardiomyopathy with LVEF≤35% who underwent cardiac magnetic resonance imaging were consecutively enrolled in this study. The primary end point is a composite of SCD or aborted SCD and the second end point is a composite of heart failure death and heart transplantation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Over a median follow-up of 86.3 months, 101 patients reached the primary end point. In the adjusted analysis, age (hazard ratio [HR], 1.02 [95% CI, 1.01-1.04]; <i>P</i>=0.006) years, a family history of SCD (HR, 2.00 [95% CI, 1.01-3.98]; <i>P</i>=0.05), NT-proBNP (N-terminal pro-B-type natriuretic peptide) (HR, 2.02 [95% CI, 1.18-3.44]; <i>P</i>=0.01), LVEF (per 5% HR, 0.79 [95% CI, 0.66-0.95]; <i>P</i>=0.01), and late gadolinium enhancement≥7.5% (HR, 4.11[95% CI, 2.72-6.21]; <i>P</i>&lt;0.001) were associated with SCD or aborted SCD. Left atrial volume index≥68.3 mL/m<sup>2</sup> was an independent predictor of the secondary end point (adjusted HR, 1.65 [95% CI, 1.13-2.40]; <i>P</i>=0.009). Compared with late gadolinium enhancement&lt;7.5%, patients with late gadolinium enhancement≥7.5% and LVEF≤20% had a 7.12-fold higher risk of experiencing SCD events in competing Cox analysis (annual event rate, 4.8%).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Patients with dilated cardiomyopathy with late gadolinium enhancement≥7.5% were at heightened risk of SCD events, which can be used for risk assessment. Risk stratifications for SCD, combining clinical and cardiac magnetic resonance imaging may potentially guide decision-making for implantable cardioverter defibrillator therapy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40100943/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319205424&v=2.18.0.post9+e462414">40100943</a> | DOI:<a href=https://doi.org/10.1161/CIRCIMAGING.124.017246>10.1161/CIRCIMAGING.124.017246</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40100943</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Di Zhou</dc:creator>
<dc:creator>Leyi Zhu</dc:creator>
<dc:creator>Shuang Li</dc:creator>
<dc:creator>Weichun Wu</dc:creator>
<dc:creator>Baiyan Zhuang</dc:creator>
<dc:creator>Jing Xu</dc:creator>
<dc:creator>Wenjing Yang</dc:creator>
<dc:creator>Jian He</dc:creator>
<dc:creator>Yining Wang</dc:creator>
<dc:creator>Yuhui Zhang</dc:creator>
<dc:creator>Guanshu Liu</dc:creator>
<dc:creator>Xiaoxin Sun</dc:creator>
<dc:creator>Qiang Zhang</dc:creator>
<dc:creator>Zhongzhao Teng</dc:creator>
<dc:creator>Arlene Sirajuddin</dc:creator>
<dc:creator>Andrew E Arai</dc:creator>
<dc:creator>Shihua Zhao</dc:creator>
<dc:creator>Minjie Lu</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Circulation. Cardiovascular imaging</dc:source>
<dc:title>Prognosis and Risk Stratification in Dilated Cardiomyopathy With LVEF≤35%: Cardiac MRI Insights for Better Outcomes</dc:title>
<dc:identifier>pmid:40100943</dc:identifier>
<dc:identifier>doi:10.1161/CIRCIMAGING.124.017246</dc:identifier>
</item>
<item>
<title>Can We Make the Next Step in Precision Risk Stratification of Dilated Cardiomyopathy?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40100942/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319205424&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Cardiovasc Imaging. 2025 Mar;18(3):e018057. doi: 10.1161/CIRCIMAGING.125.018057. Epub 2025 Mar 18.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40100942/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319205424&v=2.18.0.post9+e462414">40100942</a> | DOI:<a href=https://doi.org/10.1161/CIRCIMAGING.125.018057>10.1161/CIRCIMAGING.125.018057</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40100942</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Viren Ahluwalia</dc:creator>
<dc:creator>Brian P Halliday</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Circulation. Cardiovascular imaging</dc:source>
<dc:title>Can We Make the Next Step in Precision Risk Stratification of Dilated Cardiomyopathy?</dc:title>
<dc:identifier>pmid:40100942</dc:identifier>
<dc:identifier>doi:10.1161/CIRCIMAGING.125.018057</dc:identifier>
</item>
<item>
<title>Cognitive Function and Patient-Reported Outcomes After Cardiogenic Shock</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40100175/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319205424&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 10:S0735-1097(25)00483-8. doi: 10.1016/j.jacc.2025.02.023. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40100175/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319205424&v=2.18.0.post9+e462414">40100175</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.023>10.1016/j.jacc.2025.02.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40100175</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Eric J Hall</dc:creator>
<dc:creator>Jeff Schaffert</dc:creator>
<dc:creator>Sachin Agarwal</dc:creator>
<dc:creator>Colby R Ayers</dc:creator>
<dc:creator>Alexandra V Sykes</dc:creator>
<dc:creator>Laura H Lacritz</dc:creator>
<dc:creator>Amil M Shah</dc:creator>
<dc:creator>E Wesley Ely</dc:creator>
<dc:creator>C Munro Cullum</dc:creator>
<dc:creator>Maryjane A Farr</dc:creator>
<dc:creator>James A de Lemos</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Cognitive Function and Patient-Reported Outcomes After Cardiogenic Shock</dc:title>
<dc:identifier>pmid:40100175</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.023</dc:identifier>
</item>
<item>
<title>2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on the Evaluation and Management of Cardiogenic Shock: A Report of the American College of Cardiology Solution Set Oversight Committee</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40100174/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319205424&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 12:S0735-1097(25)00418-8. doi: 10.1016/j.jacc.2025.02.018. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40100174/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319205424&v=2.18.0.post9+e462414">40100174</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.018>10.1016/j.jacc.2025.02.018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40100174</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Shashank S Sinha</dc:creator>
<dc:creator>David A Morrow</dc:creator>
<dc:creator>Navin K Kapur</dc:creator>
<dc:creator>Rachna Kataria</dc:creator>
<dc:creator>Robert O Roswell</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on the Evaluation and Management of Cardiogenic Shock: A Report of the American College of Cardiology Solution Set Oversight Committee</dc:title>
<dc:identifier>pmid:40100174</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.018</dc:identifier>
</item>
<item>
<title>Managing Cardiogenic Shock Caused by Acute Myocardial Infarction: Invisible Challenges Revealed in a Statewide Registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40100173/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319205424&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 10:S0735-1097(25)05209-X. doi: 10.1016/j.jacc.2025.02.027. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40100173/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319205424&v=2.18.0.post9+e462414">40100173</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.027>10.1016/j.jacc.2025.02.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40100173</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Eric P Cantey</dc:creator>
<dc:creator>Aaron Lopacinski</dc:creator>
<dc:creator>Milan Seth</dc:creator>
<dc:creator>David E Hamilton</dc:creator>
<dc:creator>Elias J Dayoub</dc:creator>
<dc:creator>Siddharth Gandhi</dc:creator>
<dc:creator>Mir B Basir</dc:creator>
<dc:creator>Amir Kaki</dc:creator>
<dc:creator>Ryan D Madder</dc:creator>
<dc:creator>Devraj Sukul</dc:creator>
<dc:creator>Hitinder S Gurm</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Managing Cardiogenic Shock Caused by Acute Myocardial Infarction: Invisible Challenges Revealed in a Statewide Registry</dc:title>
<dc:identifier>pmid:40100173</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.027</dc:identifier>
</item>
<item>
<title>Respiratory Syncytial Virus and Incidence of Cardiovascular Events: A Nationwide Self-Controlled Case Series Analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40100172/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319205424&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 10:S0735-1097(25)05260-X. doi: 10.1016/j.jacc.2025.02.031. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40100172/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319205424&v=2.18.0.post9+e462414">40100172</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.031>10.1016/j.jacc.2025.02.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40100172</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Mats C Højbjerg Lassen</dc:creator>
<dc:creator>Daniel Modin</dc:creator>
<dc:creator>Niklas Dyrby Johansen</dc:creator>
<dc:creator>Pradeesh Sivapalan</dc:creator>
<dc:creator>Anders Hviid</dc:creator>
<dc:creator>Tyra Grove Krause</dc:creator>
<dc:creator>Jens Ulrik Stæhr Jensen</dc:creator>
<dc:creator>Tor Biering-Sørensen</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Respiratory Syncytial Virus and Incidence of Cardiovascular Events: A Nationwide Self-Controlled Case Series Analysis</dc:title>
<dc:identifier>pmid:40100172</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.031</dc:identifier>
</item>





























</channel>
</rss>